69466 Federal Register / Vol. 75, No. 218 / Friday, November 12, 2010 / Notices 

Drug Schedule 

Fentanyl (9801) ........................................................................................................................................................................................... II 

The company plans to manufacture 

small quantities of the listed controlled 

substances to make reference standards 

which will be distributed to their 

customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than January 11, 2011. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28516 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 26, 2010, and 

published in the Federal Register on 

April 30, 2010 (75 FR 22844), Lonza 

Riverside, 900 River Road, 

Conshohocken, Pennsylvania 19428, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Gamma hydroxybutyric acid 

(2010).

I 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

The company plans to manufacture 

bulk active pharmaceutical ingredients 

(API’s) for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Lonza Riverside to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Lonza Riverside to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28518 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 29, 2010, and 

published in the Federal Register on 

April 16, 2010, (75 FR 20001), Siemens 

Healthcare Diagnostics Inc., Attn: RA, 

100 GBC Drive, Mail Stop 514, Newark, 

Delaware 19702, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the basic classes 

of controlled substances listed in 

schedules I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Ecgonine (9180) ........................... II 

Morphine (9300) ........................... II 

The company utilizes the listed 

controlled substances in bulk to 

manufacture in-vitro diagnostic test kits. 

The company distributes the test kits for 

sale to its customers. The process used 

in manufacturing the test kits 

irreversibly alters the controlled 

substances involved in such a manner 

that they are no longer classified as 

controlled substances as defined under 

the Controlled Substances Act. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Siemens Healthcare Diagnostics Inc. to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Siemens Healthcare 

Diagnostics Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28531 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated June 17, 2010, and 

published in the Federal Register on 

June 28, 2010, (75 FR 36684), Varian 

Inc., 25200 Commercentre Drive, Lake 

Forest, California 92630–8810, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Phencyclidine (7471) ................................................................................................................................................................................... II 

1-Piperidinocyclohexanecarbonitrile (8603) ................................................................................................................................................ II 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 75, No. 218 / Friday, November 12, 2010 / Notices 69467 

Drug Schedule 

Benzoylecgonine (9180) .............................................................................................................................................................................. II 

The company plans to manufacture 

small quantities of the listed controlled 

substances for use in diagnostic 

products. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Varian Inc., to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated Varian 

Inc., to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28515 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated June 17, 2010, and 

published in the Federal Register on 

June 28, 2010, (75 FR 36683), Penick 

Corporation, 33 Industrial Road, 

Pennsville, New Jersey 08070, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Drug Schedule 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

The company plans to manufacture 

the listed controlled substances as bulk 

controlled substance intermediates for 

distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Penick Corporation to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Penick Corporation to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28533 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated June 17, 2010, and 

published in the Federal Register on 

June 28, 2010, (75 FR 36683), Wildlife 

Laboratories, Inc., 1401 Duff Drive, 

Suite 400, Fort Collins, Colorado 80524, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of Carfentanil (9743), a 

basic class of controlled substance listed 

in schedule II. 

The company will manufacture the 

above listed controlled substance for 

sale to veterinary pharmacies, zoos, and 

for other animal and wildlife 

applications. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Wildlife Laboratories, Inc. to 

manufacture the listed basic class of 

controlled substance is consistent with 

the public interest at this time. DEA has 

investigated Wildlife Laboratories, Inc. 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28522 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 16, 2010, and 

published in the Federal Register on 

March 24, 2010, (75 FR 14190), 

Archimica, Inc., 2460 W. Bennett Street, 

Springfield, Missouri 65807–1229, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Gamma Hydroxybutyric Acid (2010), a 

basic class of controlled substance listed 

in schedule I. 

The company plans to manufacture 

the listed controlled substance in bulk 

for sale to its customers. 

One comment and objection was 

received. However, after a thorough 

review of this matter, DEA has 

concluded that the issues raised in the 

comment and objection do not warrant 

the denial of this application. 

DEA has considered the factors in 21 

U.S.C. 823(a) and determined that the 

registration of Archimica, Inc., to 

manufacture the listed basic class of 

controlled substance is consistent with 

mstockstill on DSKH9S0YB1PROD with NOTICES